Navigation Links
Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007,American Psychiatric Association Annual Meeting

ROCKVILLE, Md., May 18, 2007 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. announced today that it will present four posters on iloperidone at the 160th American Psychiatric Association (APA) annual meeting which will be held at the San Diego Convention Center in San Diego, CA, from May 19 through May 24, 2007.

The following posters will be presented on May 22, 2007, 12:00 to 2:00 p.m. PDT, in the San Diego Convention Center (Sails Pavilion, Upper Level).

POSTER NR475 - Changes in Akathisia with Iloperidone, Risperidone, or Placebo Over the Course of an Acute Efficacy Trial (Peter Weiden, M.D. and Curt Wolfgang, Ph.D.)

POSTER NR476 - Iloperidone is Well Tolerated by Subjects with Renal or Hepatic Impairment in Single-Dose Clinical Pharmacokinetic Studies (Greg Sedek, M.D., Ph.D. and Curt Wolfgang, Ph.D.)

POSTER NR507 - A Pharmacokinetic (PK)-Pharmacodynamic (PD) Relationship Exists for Efficacy of Iloperidone, a Novel Investigational Atypical Antipsychotic Agent (Paolo Baroldi, M.D., Ph.D. and Curt Wolfgang, Ph.D.)

POSTER NR508 - Genotyping Facilitates Individualized Prediction of Pharmacokinetic Exposure of Iloperidone in Extensive and Poor CYP2D6 Metabolizers (Curt Wolfgang, Ph.D.)

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and has recently completed its Phase III program in schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatmen
'"/>




Page: 1 2

Related medicine technology :

1. Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the Annual Meeting of the Associated Professional Sleep Societies
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:10/22/2014)... , Oct. 22, 2014 Sanomedics International Holdings, ... report by Global Research & Data Services, demand for ... from 2014 through 2018, as demand for more accurate ... is the world,s largest market for thermometers, and ... thermometers is Sanomedics International Holdings, Inc. Sanomedics ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 ... announced they have entered into a license and ... to target cancers. PhosImmune possesses technology ... the surfaces of tumor cells in association with ... from proteins that play a role in malignancy, ...
(Date:10/22/2014)... 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... IAP310 study have been published in Regional ... journal with broad, multidisciplinary readership. IAP310 was a ... and efficacy of Zalviso, also referred to as ... treatment of post-operative pain in patients following open ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2
... Diversified Medical Equipment & Supplies Corporation ( ... long-term care and home care sectors since 1994, today announced ... more than doubled in size since its 2009 inception. ... has grown to become a significant source of revenue ...
... 2011 A growing number of illegal online ... dangerous unauthorized prescriptions, according to a new report ... (Logo: http://photos.prnewswire.com/prnh/20020422/CMULOGO ) Report ... Networking Institute (INI) and a senior systems scientist ...
Cached Medicine Technology:DMES, Inc. Announces 100 Percent Growth for Online Medical Supply Store 2CMU's Nicolas Christin Finds Web Hackers Profiting From Illegal Online Pharmacies 2
(Date:10/22/2014)... (PRWEB) October 22, 2014 ... staffing company, is happy to announce that our ... to Staffing Industry Analysts’ Staffing 100 for 2014. ... the “100 most influential people in the staffing ... Medical Solutions, the 13th-largest healthcare staffing company in ...
(Date:10/22/2014)... 2014 For Dr. Iris Hunter, a job ... an extension of her life’s mission. Her extensive experience in ... owner of FirstLight HomeCare, make it clear that Hunter’s mission ... that my work makes a difference in the lives of ... so after much research, I felt ready to start on ...
(Date:10/22/2014)... News) -- The United States is now mandating ... of West Africa land at one of five ... the virus. In a statement released Tuesday, ... percent of air passengers from Guinea, Liberia and ... five airports -- New York City,s Kennedy International ...
(Date:10/22/2014)... October 22, 2014 The ... which is dedicated to distribute health information technology ... delivery worldwide announced the development of six key ... expect when receiving healthcare. These are an expansion ... care: “providing care that is respectful of and ...
(Date:10/22/2014)... 22, 2014 With the Affordable Care Act ... by the American Institutes for Research (AIR) finds that three ... use health insurance, but 42 percent say they are not ... before signing up for coverage. , The AIR survey found ... percent able to calculate correctly how much they owe for ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4
... , MONDAY, June 27 (HealthDay News) -- ... a portable home monitoring device appear more effective than ... predicting whether patients with chronic kidney disease will experience ... an Italian study that included 436 chronic kidney disease ...
... identified six subtypes of an aggressive and difficult-to-treat ... (TNBC)." In the July issue of the ... Director Jennifer Pietenpol, Ph.D., and colleagues describe the ... identify chemotherapies to which the different subtypes respond ...
... Perspectives finds that the 2008 peat bog wildfires in NC ... cardiovascular effects. The study found a 37 percent increase ... a three day period of dense smoke exposure and the following ... in visits for asthma, 73 percent increase in visits for COPD ...
... , MONDAY, June 27 (HealthDay News) -- Although there,s been ... developmental delays, more than half still don,t routinely do so, ... of pediatricians reported always or almost always using one or ... to 35 months of age. By 2009, that number had ...
... many organisms females directly or indirectly select mates (or sperm) and ... sexual selection in plants is more complex in some ways than ... rely on external vectors, such as animals, for pollen transport. ... to affect the timing of pollen arrival, or the size and ...
... Dotinga HealthDay Reporter , MONDAY, June 27 (HealthDay News) ... type 1 diabetes show signs of risk factors for cardiovascular ... prove that type 1 diabetes, the kind that often begins ... and stroke remain rare in young people. But they do spotlight ...
Cached Medicine News:Health News:At-Home Blood Pressure Monitoring More Telling Than Doctor's Office Readings 2Health News:Different subtypes of triple-negative breast cancer respond to different therapies 2Health News:Different subtypes of triple-negative breast cancer respond to different therapies 3Health News:Many Pediatricians Aren't Testing Tots for Developmental Delays 2Health News:Many Pediatricians Aren't Testing Tots for Developmental Delays 3Health News:Female mate choice enhances offspring fitness in an annual herb 2Health News:Female mate choice enhances offspring fitness in an annual herb 3Health News:Diabetic Girls May Have Heart Risk Factors 2
Based on the clinically proven ACS MULTI-LINK Stent, ULTRA is a coronary stent system specifically designed for use in larger vessels. This innovative system utilizes a unique stent pattern to give y...
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
Medicine Products: